177Lu-edotreotide PRRT not checked
ITM Solucin GmbH · 177Lu-DOTATOC · 177Lu-Edo
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.”In the company’s words, NCT03049189 on ClinicalTrials.gov
- Tested for
- Neuroendocrine Tumors (2 trials), Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor and 1 more
- Main trialPhase 3
- “The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).”In the company’s words, NCT03049189 on ClinicalTrials.gov
- Other names
- 177Lu-DOTATOC · 177Lu-Edo · 177Lu-DOTATOC 177Lu-Edo · Lutetium Lu 177-Edotreotide · 177Lu-edotreotide
Other drugs for Neuroendocrine Tumors
- CAM2029Camurus AB · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
Coming up2
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- Jun 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 27 Nov 2024 | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients | |
| Phase 3Active, not recruiting | Jun 2027 | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE | |
| Phase 1Recruiting | Jun 2028 | Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026